Loading clinical trials...
Loading clinical trials...
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Conditions
Interventions
Rimegepant
Placebo
Locations
69
United States
Coastal Clinical Research, LLC
Mobile, Alabama, United States
Clinical Research Consortium, An AMR Company
Tempe, Arizona, United States
Radiant Research, Inc.
Tucson, Arizona, United States
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States
Woodland International Research Group, LLC
Little Rock, Arkansas, United States
Pharmacology Research Institute
Encino, California, United States
Start Date
February 27, 2018
Primary Completion Date
October 8, 2018
Completion Date
October 15, 2018
Last Updated
February 16, 2023
NCT03237845
NCT02873221
NCT02867709
NCT02848326
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions